scholarly journals Treatment with pralsetinib (formerly BLU-667), a potent and selective RET inhibitor, provides rapid clearance of ctDNA in patients with RET-altered non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC)

2019 ◽  
Vol 30 ◽  
pp. ix122 ◽  
Author(s):  
D.H. Lee ◽  
V. Subbiah ◽  
J.F. Gainor ◽  
M.H. Taylor ◽  
V.W. Zhu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Medullary Thyroid Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Medullary Thyroid ◽  
Rapid Clearance

scholarly journals Arriving at the Right Diagnosis in an Era of Precision Medicine

2016 ◽  
Vol 9 (2) ◽  
pp. 351-357
Author(s):  
Vina Pulido ◽  
Shin Yin Lee ◽  
Naomi Yu Ko
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Precision Medicine ◽  
Medullary Thyroid Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Medullary Thyroid ◽  
The Right

In the era of precision medicine and targeted therapy, diagnostic inaccuracy can have tremendous ramifications. We present the case of a 61-year-old man initially diagnosed with small cell lung cancer by pathology. Prior to initiating chemotherapy, multidisciplinary discussions led to an amendment of the diagnosis to medullary thyroid cancer.

A contemporary review of rearranged during transfection-selective inhibitors

2021 ◽  
pp. 107815522110405
Author(s):  
Angel W Liu ◽  
Connie Liang ◽  
Chung-Shien Lee
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Objective Response ◽  
Small Cell ◽  
Suppressive Therapy ◽  
Selective Inhibitors ◽  
Small Cell Lung ◽  
Pivotal Phase

Objective Rearranged during transfection genes are present in 1−2% of patients who have non-small cell lung cancer and 10−30% of patients with papillary thyroid cancer. The objective of this article is to review the current rearranged during transfection inhibitors indicated for patients with rearranged during transfection-mutated cancers and their future directions. Data sources: The pivotal phase I/II studies for selpercatinib and pralsetinib were evaluated. Current studies on rearranged during transfection inhibitors were searched on ClinicalTrials.gov using the key word “RET.” Data summary: Selpercatinib and pralsetinib were the first two U.S. Food and Drug Administration-approved rearranged during transfection-selective inhibitors for advanced or metastatic rearranged during transfection fusion-positive non-small cell lung cancer, rearranged during transfection-mutant medullary thyroid cancer, and rearranged during transfection fusion-positive thyroid cancer. Both agents showed promising efficacy with objective response rate ranging from 60% to 73% in all aforementioned rearranged during transfection-mutated cancers. Additionally, benefits were seen even in patients with intracranial metastasis at baseline. Both showed favorable safety profiles. Some common class adverse events included elevated liver function tests and hypertension. Hematologic side effects such as anemia and neutropenia were more common with pralsetinib. Selpercatinib had interactions with acid suppressive therapy and specific instructions when used concomitantly. Conclusions While the rearranged during transfection inhibitors are generally well-tolerated, each agent possesses slightly different efficacy, side-effect profile, and drug−drug interactions.

Two Cases of Non-Small Cell Lung Cancer Masquerading as Metastatic Papillary Thyroid Cancer

2012 ◽  
Vol 5 (2) ◽  
pp. 157
Author(s):  
Ju Hee Lee ◽  
Se-Hoon Lee ◽  
Hye Sook Min ◽  
Ji-hoon Kim ◽  
Do Joon Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Small Cell Lung Cancer ◽  
Papillary Thyroid Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Papillary Thyroid ◽  
Small Cell Lung

scholarly journals Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed as Lung Cancer

2018 ◽  
Vol 11 (2) ◽  
pp. 399-403 ◽  
Author(s):  
Eva J. Gordon ◽  
David Parker ◽  
Kelly Barth ◽  
Jennifer Pena ◽  
Julia A. Elvin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Small Cell ◽  
Response To Treatment ◽  
Molecular Diagnostic ◽  
Genomic Profiling ◽  
Small Cell Lung ◽  
Medullary Thyroid ◽  
Inherited Cancer

Mutations or other alterations in the RET gene have been implicated in a variety of malignancies – most commonly thyroid, but also chronic myelomonocytic leukemia, acute myeloid leukemia, and lung, breast, pancreatic, and colon cancers. Here we present a case of a gentlemen initially diagnosed with and treated for non-small cell lung adenocarcinoma. Genomic profiling of his tumor specimen revealed a RET point mutation with a known association with medullary thyroid cancer (MTC). Further pathological and molecular diagnostic evaluation confirmed a diagnosis of MTC, leading to a change in treatment from standard chemotherapy for non-small cell lung cancer to targeted therapy against RET and potential implications regarding inherited cancer risk for his offspring. The patient experienced a clinical response to treatment and several months of improved quality of life. This case illustrates the capacity of genomic profiling to uncover molecular drivers of disease and help ensure proper diagnosis and management of cancer.

Sign in / Sign up

Export Citation Format

Share Document